Scangos says the firm will keep its head down to continue controlling costs, maximizing revenues and advancing the pipeline this year.
Biogen Inc. wouldn't acknowledge rumors that it plans to sell its hemophilia business, but CEO George Scangos told analysts during a first quarter earnings call that the big biotech will be focusing on "cost control" and keeping its head down.
"For the remainder of the year, we are focused on three areas: careful control of our costs, maximizing our revenues,...
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
